|
A more recent version of this article appeared on August 1, 2005
Papers In Press, published online ahead of print May 16, 2005
J. Lipid Res., doi:10.1194/jlr.M400469-JLR200
Submitted on November 27, 2004
Revised on April 20, 2005
Accepted on May 3, 2005
Macrophage-specific expression of type IIA secretory phospholipase A2 results in accelerated early atherogenesis by increasing oxidative stress in LDL-receptor deficient mice
Uwe J. F. Tietge, Domenico Pratico, Tao Ding, Colin D. Funk, Reeni B. Hildebrand, Theo J. Van Berkel, and Miranda Van Eck
Center for Liver, Digestive and Metabolic Diseases, University of Groningen Medical Center, Groningen 9713 GZ
Corresponding Author: u_tietge{at}yahoo.com
Type IIA secretory phospholipase A2 (sPLA2) is an acute phase protein mediating decreased plasma HDL cholesterol levels and increased atherosclerosis. The aim of this study was to investigate the impact of macrophage-specific sPLA2 overexpression on lipoprotein metabolism and atherogenesis. Macrophages from sPLA2-transgenic mice express functional sPLA2 enzyme and have 2.5-times increased rates of LDL oxidation (TBARS formation) in vitro (59 ± 5 vs. 24 ± 4 nmol MDA/mg protein, resp., p<0.001) that are dependent on functional 12/15-lipoxygenase. LDLR-/- mice were transplanted with bone marrow from either sPLA2-tg mice (sPLA2LDLR-/-, n=19) or wild-type C57BL/6 littermates (C57BL/6LDLR-/-, n=19) and maintained for 8 weeks on chow, then for 9 weeks on Western-type diet. Plasma sPLA2 activity and plasma lipoprotein profiles were not significantly different between sPLA2LDLR-/- and C57BL/6LDLR-/- mice. Aortic root atherosclerosis was 57% increased in sPLA2LDLR-/- compared with C57BL/6LDLR-/- controls (231,415 ± 26,390 vs. 147,211 ± 20,679 m2, resp., p<0.05). Foam cell formation in vitro and in vivo was significantly increased. Urinary, plasma and aortic levels of the isoprostane 8,12-iso-iPF2 -VI, a specific marker of lipid peroxidation, as well as aortic levels of 12/15-lipoxygenase reaction products were each significantly higher in sPLA2LDLR-/- compared with C57BL/6LDLR-/- controls (p<0.001) indicating a significant increase of in vivo oxidative stress in sPLA2LDLR-/-. These data demonstrate that selective macrophage overexpression of human sPLA2 increases atherogenesis by directly modulating foam cell formation and in vivo oxidative stress without any effect on systemic sPLA2 activity and lipoprotein metabolism.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
W. Annema, N. Nijstad, M. Tolle, J. F. de Boer, R. V. C. Buijs, P. Heeringa, M. van der Giet, and U. J. F. Tietge
Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A2
J. Lipid Res.,
April 1, 2010;
51(4):
743 - 754.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. P. Sullivan, S. E. Seidl, C. B. Rich, M. Raymondjean, and B. M. Schreiber
Secretory Phospholipase A2, Group IIA Is a Novel Serum Amyloid A Target Gene: ACTIVATION OF SMOOTH MUSCLE CELL EXPRESSION BY AN INTERLEUKIN-1 RECEPTOR-INDEPENDENT MECHANISM
J. Biol. Chem.,
January 1, 2010;
285(1):
565 - 575.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Shaposhnik, X. Wang, J. Trias, H. Fraser, and A. J. Lusis
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002)
J. Lipid Res.,
April 1, 2009;
50(4):
623 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. J. Curfs, S. A. I. Ghesquiere, M. N. Vergouwe, I. van der Made, M. J. J. Gijbels, D. R. Greaves, J. S. Verbeek, M. H. Hofker, and M. P. J. de Winther
Macrophage Secretory Phospholipase A2 Group X Enhances Anti-inflammatory Responses, Promotes Lipid Accumulation, and Contributes to Aberrant Lung Pathology
J. Biol. Chem.,
August 1, 2008;
283(31):
21640 - 21648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Bostrom, B. B. Boyanovsky, C. T. Jordan, M. P. Wadsworth, D. J. Taatjes, F. C. de Beer, and N. R. Webb
Group V Secretory Phospholipase A2 Promotes Atherosclerosis: Evidence From Genetically Altered Mice
Arterioscler Thromb Vasc Biol,
March 1, 2007;
27(3):
600 - 606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Rosengren, H. Peilot, M. Umaerus, A.-C. Jonsson-Rylander, L. Mattsson-Hulten, C. Hallberg, P. Cronet, M. Rodriguez-Lee, and E. Hurt-Camejo
Secretory Phospholipase A2 Group V: Lesion Distribution, Activation by Arterial Proteoglycans, and Induction in Aorta by a Western Diet
Arterioscler Thromb Vasc Biol,
July 1, 2006;
26(7):
1579 - 1585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study
Hum. Mol. Genet.,
January 15, 2006;
15(2):
355 - 361.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|